Compare EDBL & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDBL | SHPH |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2021 | 2022 |
| Metric | EDBL | SHPH |
|---|---|---|
| Price | $0.83 | $5.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 145.8K | 31.0K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,810,000.00 | N/A |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $282.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $0.38 |
| 52 Week High | $17.30 | $8.88 |
| Indicator | EDBL | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 20.26 | 57.99 |
| Support Level | $0.44 | $2.92 |
| Resistance Level | $1.20 | $5.10 |
| Average True Range (ATR) | 0.06 | 0.52 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 10.81 | 71.43 |
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces. Company provides two principal product segments: (i) fresh produce, including cut herbs, hydroponic basil, potted herbs, and wheatgrass; and (ii) shelf-stable and refrigerated consumer packaged goods, including sports nutrition and nutraceuticals.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.